Novel glycan conjugates and use thereof

    公开(公告)号:NZ729243A

    公开(公告)日:2018-08-31

    申请号:NZ72924315

    申请日:2015-08-21

    Abstract: This disclosure relates to an immunogenic composition comprising (a) a glycan conjugate comprising at least one glycan with a link and a carrier wherein the or each glycan is conjugated to the carrier through the linker, and (b) optionally an adjuvant. The or each glycan with the linker has a chemical structure of formula (II) wherein R1 is selected from the group consisting of –F, -N3, -NO2, and ORA where RA is an optionally substituted aryl, and R2 is –CH3; or R1 is –OH, and R2 is selected from the group consisting of –CH2F, -CH2N3, -CH2OH, and –C=CH.

    Novel glycan conjugates and use thereof

    公开(公告)号:AU2015305332B2

    公开(公告)日:2018-04-12

    申请号:AU2015305332

    申请日:2015-08-21

    Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.

    Large scale enzymatic synthesis of oligosaccharides

    公开(公告)号:AU2016206315B2

    公开(公告)日:2017-12-14

    申请号:AU2016206315

    申请日:2016-07-21

    Abstract: Abstract A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

    Anti-HER2 glycoantibodies and uses thereof

    公开(公告)号:AU2015267045A1

    公开(公告)日:2017-01-05

    申请号:AU2015267045

    申请日:2015-05-27

    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

    Large scale enzymatic synthesis of oligosaccharides

    公开(公告)号:AU2016206315A1

    公开(公告)日:2016-08-11

    申请号:AU2016206315

    申请日:2016-07-21

    Abstract: Abstract A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

    Vacunas de Globo H y relacionadas contra el cáncer con nuevos adyuvantes glicolipídicos

    公开(公告)号:ES2570630T3

    公开(公告)日:2016-05-19

    申请号:ES09789075

    申请日:2009-08-06

    Abstract: Una composición inmunogénica que comprende: (a) un glicano que consiste esencialmente en Globo H, el antígeno-3 específico de la etapa embrionaria (SSEA-3. Gb5) y el antígeno-4 específico de la etapa embrionaria (SSEA-4, sialil-Gb5), Bb4, o un fragmento inmunogénico del mismo, en el que el glicano que se conjuga con una proteína portadora es el material 197 que presenta reacción cruzada con la toxina de la difteria (DT-CRM197) o el toxoide de la difteria, a través de un enlazante; y (b) un adyuvante de α-galactosil-ceramida (α-GalCer).

Patent Agency Ranking